Generic Biologics Will Not Be Approved For At Least Three Years, Barr CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr is “evaluating various acquisitions/joint venture opportunities” in the generic biologic arena. The firm’s preparations will become more transparent by year-end, Downey said.